Cargando…

Dual Interleukin-4/Interleukin-13 Blocker-induced Arthralgia Treated Successfully with Upadacitinib in a Patient with Atopic Dermatitis

Detalles Bibliográficos
Autores principales:	TANJI, Takayuki, WATABE, Daisuke, ARAKAWA, Nobuyuki, KAMADA, Hirofumi, AMANO, Hiroo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society for Publication of Acta Dermato-Venereologica 2023
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158828/ https://www.ncbi.nlm.nih.gov/pubmed/37186170 http://dx.doi.org/10.2340/actadv.v103.5326

Ejemplares similares

Targeting Interleukin 13 for the Treatment of Atopic Dermatitis
por: Lytvyn, Yuliya, et al.
Publicado: (2023)

Atopic Dermatitis and Ulcerative Colitis Successfully Treated with Upadacitinib
por: Grieco, Teresa, et al.
Publicado: (2023)

Exacerbation of human papillomavirus infection with initiation of upadacitinib for atopic dermatitis
por: Seale, Emily, et al.
Publicado: (2023)

The hidden sentinel of the skin: An overview on the role of interleukin-13 in atopic dermatitis
por: Napolitano, Maddalena, et al.
Publicado: (2023)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
por: Nogueira, Miguel, et al.
Publicado: (2021)

Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults
por: De Greef, Axel, et al.
Publicado: (2023)

Atopic dermatitis treated with tralokinumab and upadacitinib combination therapy: A case report
por: Lansang, Rafael Paolo, et al.
Publicado: (2023)

Association analysis of non-synonymous polymorphisms of interleukin-4 receptor-α and interleukin-13 genes in canine atopic dermatitis
por: TANAKA, Kazuaki, et al.
Publicado: (2020)

An Interleukin-4 and Interleukin-13 Induced Atopic Dermatitis Human Skin Equivalent Model by a Skin-On-A-Chip
por: Kim, Kyunghee, et al.
Publicado: (2022)

Upadacitinib improved alopecia areata in a patient with atopic dermatitis: A case report
por: Cantelli, Mariateresa, et al.
Publicado: (2022)

Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

Interleukin 1-β, interleukin-1 receptor antagonist and vitamin D levels in children with atopic dermatitis
por: Machura, Edyta, et al.
Publicado: (2018)

Changes in induced regulatory T cells by interleukin 35 during atopic dermatitis
por: Tavakolpour, Soheil
Publicado: (2016)

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
por: Nezamololama, Novin, et al.
Publicado: (2020)

Effectiveness and Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
por: Hagino, Teppei, et al.
Publicado: (2023)

Acne keloidalis nuchae in a patient with atopic dermatitis treated with Janus kinase inhibitor upadacitinib
por: Caudrelier, Nicolas, et al.
Publicado: (2023)

Association of reduced count of interleukin-13-producing cells in breast milk with atopic dermatitis in infancy
por: Moradkhani, Sepideh, et al.
Publicado: (2018)

Bridging to a selective Janus kinase 1 inhibitor in severe atopic dermatitis: An instructive case with upadacitinib
por: Nguyen, Jannett, et al.
Publicado: (2020)

Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: A case report
por: Bourkas, Adrienn N, et al.
Publicado: (2022)

The Eosinophil-to-Lymphocyte Ratio Acts as an Indicator for Improvement of Clinical Signs and Itch by Upadacitinib Treatment in Atopic Dermatitis
por: Hagino, Teppei, et al.
Publicado: (2023)

Acne Among Japanese Patients with Atopic Dermatitis Receiving Upadacitinib in the Phase 3 Rising Up Study
por: Hayashi, Nobukazu, et al.
Publicado: (2023)

Serum levels and single nucleotide polymorphisms of the interleukin-33 gene in atopic dermatitis
por: Zaryczañska, Anna, et al.
Publicado: (2022)

Increased Interleukin-36β Expression Promotes Angiogenesis in Japanese Atopic Dermatitis
por: Komaki, Reo, et al.
Publicado: (2023)

Skin Barrier and Inflammation Genes Associated with Atopic Dermatitis are Regulated by Interleukin-13 and Modulated by Tralokinumab In vitro
por: TOLLENAERE, Maxim A. X., et al.
Publicado: (2021)

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: A network meta‐analysis
por: Wan, Huiying, et al.
Publicado: (2022)

Correlation between serum interleukin-31 level and the severity of disease in children with atopic dermatitis
por: Siniewicz-Luzeńczyk, Katarzyna, et al.
Publicado: (2013)

Aberrant Wound Healing in an Epidermal Interleukin-4 Transgenic Mouse Model of Atopic Dermatitis
por: Zhao, Yan, et al.
Publicado: (2016)

Interleukin-31 Receptor A Expression in the Dorsal Root Ganglion of Mice with Atopic Dermatitis
por: Arai, Iwao, et al.
Publicado: (2023)

Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments
por: Makowska, Karolina, et al.
Publicado: (2023)

DETECTION OF R576 INTERLEUKIN-4 RECEPTOR AN ALLELE GENE, SERUM INTERLEUKIN-4, AND EOSINOPHILIC CATIONIC PROTEIN IN ATOPIC DERMATITIS PATIENTS
por: Abdel-Mawla, M Y, et al.
Publicado: (2009)

Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study
por: Chiricozzi, Andrea, et al.
Publicado: (2022)

In vitro interleukin 4 and interferon-gamma production by mononuclear cells from atopic dermatitis patients
por: Well, Serge, et al.
Publicado: (1993)

Correction: Aberrant Wound Healing in an Epidermal Interleukin-4 Transgenic Mouse Model of Atopic Dermatitis
por: Zhao, Yan, et al.
Publicado: (2016)

Measuring serum concentrations of interleukin-33 in atopic dermatitis is associated with potential false positive results
por: Nygaard, Uffe, et al.
Publicado: (2016)

Evaluation of the effect of the interleukin-25 serum concentration on the intensity of the symptoms of atopic dermatitis and epidermal barrier
por: Basałygo, Magdalena, et al.
Publicado: (2021)

Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: 2-Year Interim Results from the Phase 3 Rising Up Study
por: Katoh, Norito, et al.
Publicado: (2022)

Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry
por: BOESJES, Celeste M., et al.
Publicado: (2023)

Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis
por: Gao, Qin, et al.
Publicado: (2023)

Relationship between serum 25-hydroxyvitamin D and interleukin-31 levels, and the severity of atopic dermatitis in children
por: Cheon, Bo Ram, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_dlhia7cbo34ouunam64eal1a1q